| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1726 | 2020 |
| Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC J Yun, SH Lee, SY Kim, SY Jeong, JH Kim, KH Pyo, CW Park, SG Heo, ... Cancer Discovery 10 (8), 1194-1209, 2020 | 246 | 2020 |
| Comparative analysis of gut microbiota associated with body mass index in a large Korean cohort Y Yun, HN Kim, SE Kim, SG Heo, Y Chang, S Ryu, H Shin, HL Kim BMC microbiology 17, 1-9, 2017 | 181 | 2017 |
| Repotrectinib exhibits potent antitumor activity in treatment-naïve and solvent-front–mutant ROS1-rearranged non–small cell lung cancer MR Yun, DH Kim, SY Kim, HS Joo, YW Lee, HM Choi, CW Park, SG Heo, ... Clinical Cancer Research 26 (13), 3287-3295, 2020 | 99 | 2020 |
| Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma SY Kim, SM Kim, S Lim, JY Lee, SJ Choi, SD Yang, MR Yun, CG Kim, ... Clinical Cancer Research 27 (15), 4397-4409, 2021 | 87 | 2021 |
| Meta-analysis of genome-wide SNP-and pathway-based associations for facets of neuroticism SE Kim, HN Kim, YJ Yun, SG Heo, J Cho, MJ Kwon, Y Chang, S Ryu, ... Journal of human genetics 62 (10), 903-909, 2017 | 39 | 2017 |
| Preclinical study of a biparatopic METxMET antibody–drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC SY Oh, YW Lee, EJ Lee, JH Kim, YJ Park, SG Heo, MR Yu, MH Hong, ... Clinical Cancer Research 29 (1), 221-232, 2023 | 34 | 2023 |
| Male-specific genetic effect on hypertension and metabolic disorders SG Heo, JY Hwang, S Uhmn, MJ Go, B Oh, JY Lee, JW Park Human genetics 133, 311-319, 2014 | 34 | 2014 |
| Patient-derived cells to guide targeted therapy for advanced lung adenocarcinoma SY Kim, JY Lee, DH Kim, HS Joo, MR Yun, D Jung, J Yun, SG Heo, ... Scientific reports 9 (1), 19909, 2019 | 33 | 2019 |
| Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer BC Ahn, JW So, CB Synn, TH Kim, JH Kim, Y Byeon, YS Kim, SG Heo, ... European Journal of Cancer 153, 179-189, 2021 | 26 | 2021 |
| Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models SM Lim, SD Yang, S Lim, SG Heo, S Daniel, A Markovets, R Minoo, ... Therapeutic Advances in Medical Oncology 14, 17588359221079125, 2022 | 15 | 2022 |
| Personalized biomarker-based umbrella trial for patients with recurrent or metastatic head and neck squamous cell carcinoma: KCSG HN 15-16 TRIUMPH trial B Keam, MH Hong, SH Shin, SG Heo, JE Kim, HK Ahn, YG Lee, KU Park, ... Journal of Clinical Oncology 42 (5), 507-517, 2024 | 14 | 2024 |
| Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma MH Hong, SG Heo, YG Lee, HS Kim, KU Park, HG Kim, YH Ko, IJ Chung, ... Cancer 126 (20), 4521-4531, 2020 | 14 | 2020 |
| SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models CB Synn, SE Kim, HK Lee, MH Kim, JH Kim, JM Lee, HN Jo, W Lee, ... Clinical & Translational Immunology 11 (1), e1364, 2022 | 11 | 2022 |
| The liability threshold model for predicting the risk of cardiovascular disease in patients with type 2 diabetes: a multi-cohort study of Korean adults EP Hong, SG Heo, JW Park Metabolites 11 (1), 6, 2020 | 11 | 2020 |
| A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma JH Lee, SG Heo, BC Ahn, MH Hong, BC Cho, SM Lim, HR Kim Cancer medicine 10 (20), 7012-7020, 2021 | 10 | 2021 |
| Incorporation of SKI-G-801, a novel AXL inhibitor, with anti-PD-1 plus chemotherapy improves anti-tumor activity and survival by enhancing T cell immunity W Lee, DK Kim, CB Synn, HK Lee, S Park, DS Jung, Y Choi, JH Kim, ... Frontiers in Oncology 12, 821391, 2022 | 9 | 2022 |
| Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia SG Heo, Y Koh, JK Kim, J Jung, HL Kim, SS Yoon, JW Park BMC Medical Genetics 18, 1-7, 2017 | 8 | 2017 |
| Genetic risk prediction for normal-karyotype acute myeloid leukemia using whole-exome sequencing SG Heo, EP Hong, JW Park Genomics & informatics 11 (1), 46, 2013 | 7 | 2013 |
| Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy JB Lee, HS Park, SJ Choi, SG Heo, HJ An, HR Kim, MH Hong, SM Lim, ... Therapeutic Advances in Medical Oncology 14, 17588359221141761, 2022 | 2 | 2022 |
